Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249796475> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4249796475 abstract "Abstract Background: Chemo-resistance in hepatocellular carcinoma (HCC) is a major problem, and acquired drug resistance prevents cancer therapies from achieving complete responses. Molecular targeting therapy presents an opportunity to impede tumor through combination or sequential therapy, while the accurate effect is vague. Methods: The efficacy of combinations between oxaliplatin and anti-cancer molecular targeting drugs was screened. Strangely, the combined chemotherapy with oxaliplatin and saracatinib induced significantly antagonistic effects. Then the antitumor effects of combined treatment with saracatinib and oxaliplatin were confirmed in wide type HCC as well as in saracatinib- and oxaliplatin-resistant HCC. RNA sequencing was used to explore the resistance mechanism, and the roles of ABCG1 and Wnt signaling in oxaliplatin resistance were confirmed. Results: Chemotherapy with oxaliplatin and saracatinib individually induced strong anti-HCC effects, while combined or sequential treatment of HCC cells with these two drugs exhibited reduced efficacy compared to treatment with the single drugs. And it was saracatinib treatment caused oxaliplatin resistance. RNA sequencing revealed 458 genes that were altered by treatment with saracatinib and oxaliplatin. Of these, the gene encoding the ATP-binding cassette transporter G1 ABCG1 and Wnt-associated genes were significantly upregulated. Upregulation of ABCG1 and oxaliplatin resistance were associated with activation of Wnt signaling. Interference with ABCG1 expression or inhibition of Wnt signaling resulted in reversal of the saracatinib-induced oxaliplatin resistance in HCC. Conclusions: These studies demonstrated that combined or sequential chemotherapy with oxaliplatin and saracatinib reduced antitumor efficacy, and this antagonism was attributed to the activation of Wnt signaling and upregulation of ABCG1 by saracatinib." @default.
- W4249796475 created "2022-05-12" @default.
- W4249796475 creator A5006069003 @default.
- W4249796475 creator A5029709809 @default.
- W4249796475 creator A5032115103 @default.
- W4249796475 creator A5032992180 @default.
- W4249796475 creator A5040845944 @default.
- W4249796475 creator A5051993838 @default.
- W4249796475 creator A5063103049 @default.
- W4249796475 creator A5066305013 @default.
- W4249796475 creator A5068347254 @default.
- W4249796475 creator A5081595540 @default.
- W4249796475 date "2019-12-11" @default.
- W4249796475 modified "2023-09-30" @default.
- W4249796475 title "Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma" @default.
- W4249796475 doi "https://doi.org/10.21203/rs.2.10292/v3" @default.
- W4249796475 hasPublicationYear "2019" @default.
- W4249796475 type Work @default.
- W4249796475 citedByCount "0" @default.
- W4249796475 crossrefType "posted-content" @default.
- W4249796475 hasAuthorship W4249796475A5006069003 @default.
- W4249796475 hasAuthorship W4249796475A5029709809 @default.
- W4249796475 hasAuthorship W4249796475A5032115103 @default.
- W4249796475 hasAuthorship W4249796475A5032992180 @default.
- W4249796475 hasAuthorship W4249796475A5040845944 @default.
- W4249796475 hasAuthorship W4249796475A5051993838 @default.
- W4249796475 hasAuthorship W4249796475A5063103049 @default.
- W4249796475 hasAuthorship W4249796475A5066305013 @default.
- W4249796475 hasAuthorship W4249796475A5068347254 @default.
- W4249796475 hasAuthorship W4249796475A5081595540 @default.
- W4249796475 hasBestOaLocation W42497964751 @default.
- W4249796475 hasConcept C104317684 @default.
- W4249796475 hasConcept C121608353 @default.
- W4249796475 hasConcept C126322002 @default.
- W4249796475 hasConcept C127561419 @default.
- W4249796475 hasConcept C137620995 @default.
- W4249796475 hasConcept C2776694085 @default.
- W4249796475 hasConcept C2780962732 @default.
- W4249796475 hasConcept C502942594 @default.
- W4249796475 hasConcept C526805850 @default.
- W4249796475 hasConcept C54355233 @default.
- W4249796475 hasConcept C62478195 @default.
- W4249796475 hasConcept C71924100 @default.
- W4249796475 hasConcept C86803240 @default.
- W4249796475 hasConceptScore W4249796475C104317684 @default.
- W4249796475 hasConceptScore W4249796475C121608353 @default.
- W4249796475 hasConceptScore W4249796475C126322002 @default.
- W4249796475 hasConceptScore W4249796475C127561419 @default.
- W4249796475 hasConceptScore W4249796475C137620995 @default.
- W4249796475 hasConceptScore W4249796475C2776694085 @default.
- W4249796475 hasConceptScore W4249796475C2780962732 @default.
- W4249796475 hasConceptScore W4249796475C502942594 @default.
- W4249796475 hasConceptScore W4249796475C526805850 @default.
- W4249796475 hasConceptScore W4249796475C54355233 @default.
- W4249796475 hasConceptScore W4249796475C62478195 @default.
- W4249796475 hasConceptScore W4249796475C71924100 @default.
- W4249796475 hasConceptScore W4249796475C86803240 @default.
- W4249796475 hasLocation W42497964751 @default.
- W4249796475 hasLocation W42497964752 @default.
- W4249796475 hasLocation W42497964753 @default.
- W4249796475 hasOpenAccess W4249796475 @default.
- W4249796475 hasPrimaryLocation W42497964751 @default.
- W4249796475 hasRelatedWork W10105718 @default.
- W4249796475 hasRelatedWork W12041411 @default.
- W4249796475 hasRelatedWork W17437393 @default.
- W4249796475 hasRelatedWork W18055605 @default.
- W4249796475 hasRelatedWork W19073498 @default.
- W4249796475 hasRelatedWork W2929250 @default.
- W4249796475 hasRelatedWork W4395767 @default.
- W4249796475 hasRelatedWork W5346711 @default.
- W4249796475 hasRelatedWork W9649811 @default.
- W4249796475 hasRelatedWork W3626836 @default.
- W4249796475 isParatext "false" @default.
- W4249796475 isRetracted "false" @default.
- W4249796475 workType "article" @default.